Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by efields on Wednesday November 10, 2021 @11:04AM
(#29176214)
How does this get commercialized? I can't think of anything that's inherently cheap and easy to produce that you use for a few weeks and then never again that is also a financial cash cow the way most pharmaceuticals are. Disclaimer: I work for a pharma.
[ Parent
| on HN ]
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by rednerrus on Wednesday November 10, 2021 @11:11AM
(#29176313)
The money is in the professional therapists who administer this. It's the same model that's currently working for Ketamine.
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by curuinor on Wednesday November 10, 2021 @11:11AM
(#29176312)
They figured out how to jack up the price of ketamine 100x by making it esketamine - find an analog, shove in an acetyl group somewhere, something something chiral something
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by kemayo on Wednesday November 10, 2021 @11:36AM
(#29176679)
It's probably not "a few weeks and then never again" -- I'm not depressed, but anecdotes from people I know who've tried mushrooms at home for this suggest that one trip produces a noticeable improvement that fades over time.
It's possible that the full experience with a trained therapist who supervises the trip could produce longer-lasting changes, of course.
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by forgotmypw17 on Wednesday November 10, 2021 @12:04PM
(#29177079)
Why does it have to be commercialized?
Personally, I think the best option is it gets mainstreamed by knowledgeble guides working with individuals through the process, the mushroom growing is done by small-scale growers who do it with the passion and love this Medicine deserves, and the pill-makers are kept far and away from it.
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by spyder on Wednesday November 10, 2021 @01:55PM
(#29178790)
Why does it have to be commercialized?
In general it doesn't has to be, but in this case the research is done by a for-profit company which expects to see a return on their investments.
Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by forgotmypw17 on Wednesday November 10, 2021 @04:14PM
(#29180906)
Ah, good point.